At the news
? NEUTRALIMPACT 3/10 CLUSTER filed Mar 2, 2026 at 19:00 ET
Seven Alnylam Pharmaceuticals insiders executed trades over the past week, with three C-suite executives selling a combined $257,499 in shares on the open market, while five executives received non-cash stock awards totaling 27,070 shares. The sales were small in magnitude relative to the company's $42.5B market cap.
- Three C-suite executives (CSO, CCO, CFO, Chief R&D) sold shares in open-market transactions totaling $257,499 over four days.
- CEO Yvonne Greenstreet and four other executives received non-cash stock awards totaling 27,070 shares, valued at $0 in transaction value.
- All open-market sales occurred at prices between $316.55 and $321.81 per share.
- Total dollar value of open-market sales represents just 0.0006% of Alnylam's $42.5B market cap.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access